Skip to content
Home/Companies/Biotech/Pathalys Pharma
PP

Pathalys Pharma

Biotech·US·Active·3yr hold

Pathalys Pharma is a biotech company, headquartered in US.

Entry
2023
Hold
3yr
Status
Active
Est. EV
–

Who owns Pathalys Pharma?

Pathalys Pharma is currently owned by Abingworth through Abingworth Bioventures 8 (2021 vintage), since 2023.

Hand-verified · updated 2026-06-10

Abingworth
Investor
Abingworth
Abingworth Bioventures 8 · 2021 · Life Sciences VC

Key facts

HQUS
SectorBiotech
StatusActive

More from Abingworth Bioventures 8

Other portfolio companies in the same fund.

Cytospire Therapeutics
Active
BiotechUK· 2026
AdvanCell
Active
BiotechAustralia· 2025
Antares Therapeutics
Active
BiotechUS· 2025
Solve Therapeutics
Active
BiotechUS· 2025
Timberlyne Therapeutics
Active
HealthcareUS· 2025
Myricx Bio
Active
BiotechUK· 2024

More PE-backed in Biotech

Comparable biotech deals from other GPs.

GenSight Biologics
Active
Sofinnova PartnersFrance
InBrain Pharma
Active
Finovam GestionFrance
Isavy Biotech
Active
Ring CapitalFrance
NeoVacs
Active
Odyssée VentureFrance
ReNeuron Group
Exited 2024
Obotritia CapitalUnited Kingdom
Univercells
Exited 2023
AdBio PartnersBelgium
to
Data refreshed weekly · Sourced from public filings